Mirna Therapeutics, a clinical-stage biotechnology company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the appointment of Lawrence M. Alleva, a former partner with PricewaterhouseCoopers LLP, as an outside director to its Board of Directors.
“We are excited to have Larry join our distinguished group of directors. As a finance professional with more than 30 years of experience in technology industries, his expertise and guidance will be invaluable to Mirna as we continue to build our company along with driving forward the clinical program for MRX34, the first microRNA Replacement Therapy in clinical trials,” said Dr. Paul Lammers, President and Chief Executive Officer of Mirna.
Help employers find you! Check out all the jobs and post your resume.
